"What" Series

What is FIC in Life Sciences?

4 October 2023
2 min read

FIC stands for First in Class, which refers to pioneering drugs. These are identified by discovering new drug targets, mechanisms of action, and molecular structures, gradually synthesizing candidate compounds from scratch. Through repeated trials and screenings, drugs are finally discovered that meet both therapeutic efficacy and human safety requirements (tolerability, pharmacodynamics).

Keep Reading
Back to all blogs →
Edgewise Therapeutics Launches Worldwide Crucial Trial of EDG-5506 for Becker Muscular Dystrophy, Called GRAND CANYON
Latest Hotspot
3 min read
Edgewise Therapeutics Launches Worldwide Crucial Trial of EDG-5506 for Becker Muscular Dystrophy, Called GRAND CANYON
3 October 2023
Edgewise Therapeutics, Inc., has initiated the participation induction for GRAND CANYON, an international principal examination of EDG-5506 designed for Becker patients.
Read →
Arcturus Therapeutics and the Cystic Fibrosis Foundation are collaborating on the production of ARCT-032, a possible mRNA treatment for Cystic Fibrosis
Latest Hotspot
3 min read
Arcturus Therapeutics and the Cystic Fibrosis Foundation are collaborating on the production of ARCT-032, a possible mRNA treatment for Cystic Fibrosis
3 October 2023
Arcturus Therapeutics and the Cystic Fibrosis Foundation continue partnership to further the development of ARCT-032, an experimental mRNA therapy for Cystic Fibrosis.
Read →
ROCK2 inhibitors help to restore immune balance
Valuable Targets
6 min read
ROCK2 inhibitors help to restore immune balance
3 October 2023
ROCK, also known as Rho-associated coiled-coil kinases, is a class of serine/threonine protein kinases that play an important role in various common cellular functions such as cell proliferation, cell apoptosis, and gene expression.
Read →
Inozyme Pharma reports promising initial results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies
Latest Hotspot
3 min read
Inozyme Pharma reports promising initial results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies
3 October 2023
Inozyme Pharma reports encouraging preliminary results from ongoing INZ-701 phase 1/2 studies in adults with ENPP1 and ABCC6 (PXE) deficiencies.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.